Saudi Arabia · Obesity · GLP-1 market research

    Obesity & GLP-1 Market Research in Saudi Arabia

    BioNixus does obesity market research in Saudi Arabia: GLP-1 physician surveys, patient-journey and persistence studies, and payer and access interviews. Saudi fieldwork runs from the Al Khobar partner office for KSA. Cairo is the AMEA (APAC, Middle East, Africa) office, and the USA is the Americas office and global HQ in Sheridan, Wyoming. It is commissioned primary research, not a syndicated pack, at $10,000–$60,000, with a costed proposal within one working day.

    See the healthcare market research hub.

    The modules below cover physician KAP, semaglutide and tirzepatide, patient discontinuation, and SFDA, NUPCO, and CHI access. Arabic and English fieldwork is standard.

    Last reviewed: 27 October 2026

    Request a $10,000–$60,000 scoped proposalSee what we research

    $10,000–$60,000

    custom studies

    82,000+ physicians globally and about 3,200 physicians in the Middle East

    physician network

    127

    studies year-to-date in 2026

    Al Khobar

    partner office for KSA

    Quick answer

    Who does obesity market research in Saudi Arabia?

    BioNixus does obesity market research in Saudi Arabia. The work is commissioned primary research, not a syndicated pack, typically $10,000–$60,000, with a costed proposal within one working day.

    • Physician surveys and KAP studiesPhysician surveys and KAP studies across endocrinology, family medicine, internal medicine, and bariatric surgery.
    • Semaglutide and tirzepatide modulesInitiation, switching, and indication-mix questions on semaglutide and tirzepatide, including diabetes versus obesity use.
    • SFDA, NUPCO, and CHI access contextPayer and formulary interviews that separate public, insured, and self-pay routes for weight-management therapy.
    • Patient journey and discontinuationPatient journey and discontinuation research on initiation, persistence, and reasons patients stop therapy.
    • Bariatric referral and pharmacotherapyHow bariatric referral interacts with pharmacotherapy across surgery, clinic, and prescribing pathways.
    • Arabic and English fieldworkArabic and English fieldwork from the Al Khobar partner office for KSA. Cairo is the AMEA (APAC, Middle East, Africa) office, and the USA is the Americas office and global HQ in Sheridan, Wyoming.

    BioNixus runs physician surveys and KAP studies across endocrinology, family medicine, internal medicine, and bariatric surgery, plus patient-journey and discontinuation work and SFDA, NUPCO, and CHI access interviews, in Arabic and English. Saudi fieldwork is from the Al Khobar partner office for KSA. Cairo is the AMEA (APAC, Middle East, Africa) office. The UK is the Europe office. The USA is the Americas office and global HQ in Sheridan, Wyoming. Dubai is a field office for UAE. Kuwait is a field office for Kuwait. The physician network is 82,000+ physicians globally and about 3,200 physicians in the Middle East, with 127 studies year-to-date in 2026.

    Fit

    BioNixus vs syndicated obesity publishers in Saudi Arabia

    Research needWho does it
    Published market-size packKen Research, IMARC, Euromonitor, Mordor, Grand View
    Named HCP quotas, Arabic fieldwork, and molecule-level semaglutide/tirzepatide modulesBioNixus
    Syndicated Rx auditsIQVIA, plus BioNixus for primary research
    Brand trackingKantar
    RetailNielsenIQ

    Publisher names are plain text. The table compares research type. It does not claim guaranteed accuracy.

    Cited figures

    Key figures for Saudi obesity and GLP-1 market research

    • Independent national survey of Saudi clinicians (n=92; 2024 fieldwork published on PMC): endocrinologists prescribed anti-obesity medicines more frequently than family physicians (90.0% vs 60.5%); GLP-1 receptor agonists were the most commonly reported first-line anti-obesity medicines. This is an independent academic survey, not a BioNixus study. PMC12366907
    • BioNixus delivery facts: 82,000+ physicians globally and about 3,200 physicians in the Middle East in the healthcare network; 127 studies year-to-date in 2026; custom obesity and GLP-1 projects typically $10,000–$60,000.

    Coverage

    What BioNixus runs for obesity market research in Saudi Arabia

    GLP-1 physician surveys and KAP studies

    Commissioned physician surveys among endocrinology, family medicine, internal medicine, bariatric surgery, and obesity-clinic physicians on initiation, monitoring, and comfort with anti-obesity medicines.

    Semaglutide and tirzepatide initiation and switching

    Molecule-level questions on semaglutide and tirzepatide: dose escalation, diabetes versus obesity indication mix, supply interruptions, and self-pay versus covered use.

    SFDA, NUPCO, and CHI access interviews

    Payer and formulary interviews on public procurement, Council of Health Insurance (CHI) plan design, prior authorisation, and out-of-pocket exposure.

    Patient journey and discontinuation research

    Where patients first seek help, what they expect, and how cost, tolerability, and monitoring burden drive discontinuation.

    Bariatric referral and pharmacotherapy

    Referral routes into surgery and how pharmacotherapy substitutes for, delays, or complements bariatric and metabolic procedures.

    Pharmacy channel and supply behaviour

    Dispensing across retail and hospital pharmacies, stock behaviour during constrained supply, and cash-pay dynamics for incretin therapies.

    Breakdown

    Competing treatment routes in Saudi obesity market research

    Prescription anti-obesity medicines

    Incretin-based and other approved weight-management therapies. Physician survey work tracks access route, monthly cost exposure, and persistence.

    Bariatric and metabolic surgery

    Sleeve gastrectomy, bypass, and revisional procedures across public and private centres, and how surgical demand responds to effective pharmacotherapy.

    Endoscopic and device-based interventions

    Intragastric balloons, endoscopic sleeve procedures, and related devices positioned between lifestyle management and definitive surgery.

    Obesity clinics and multidisciplinary programmes

    Physician-led weight-management services combining pharmacotherapy, dietetics, behavioural support, and monitoring, usually sold as private packages.

    Adjacent consumer and OTC categories

    Meal replacement, nutraceutical, and wellness products that shape patient expectations and compete for the same out-of-pocket budget.

    What is moving

    Demand context for obesity market research in Saudi Arabia

    High metabolic disease burden

    Obesity and type 2 diabetes prevalence in the Gulf is among the highest globally, creating a large clinically eligible population across public and private sectors.

    Incretin-based therapy availability

    Effective pharmacological weight management has shifted patient expectations and brought previously untreated people into active medical care.

    Vision 2030 and Quality of Life Program

    National priorities on physical activity, nutrition, and healthy weight legitimise investment in prevention and weight management.

    Established bariatric surgery capacity

    Surgical capability in public and private centres means patients have a definitive option, so treatment-route competition is direct.

    Private insurance under CHI

    Council of Health Insurance (CHI) cover across the private workforce is a potential funding route, though weight-management coverage remains inconsistent.

    Self-pay demand

    A substantial share of pharmacotherapy and clinic demand is out of pocket, so price sensitivity and persistence sit at the centre of any forecast.

    Market structure

    Access structure for obesity market research in Saudi Arabia

    The Saudi obesity conversation is no longer GLP-1 in the abstract. Commercial teams brief research on semaglutide (injectable weight-management and diabetes brands in class) and tirzepatide (dual GIP/GLP-1), alongside other incretin-based and legacy anti-obesity medicines. BioNixus physician surveys ask molecule-level questions: initiation criteria, dose escalation, switching between semaglutide and tirzepatide, diabetes versus obesity indication mix, supply interruptions, and self-pay versus covered use.

    The Saudi Food and Drug Authority (SFDA) governs registration, quality, and safety communications for GLP-1 receptor agonists. BioNixus maps how SFDA registration status and safety communications affect willingness to initiate semaglutide or tirzepatide. Public volume for obesity and metabolic therapies often depends on NUPCO tendering and institutional formulary uptake, not retail awareness alone.

    Access — not awareness — still decides addressable volume for anti-obesity medicines in Saudi Arabia. Public pathways depend on formulary and procurement (including NUPCO-linked supply). Private pathways sit under Council of Health Insurance (CHI) plan design, where weight-management therapy is often treated between medical necessity and lifestyle care. The remainder is out-of-pocket through retail pharmacy and private obesity clinics. BioNixus payer and physician research separates public, insured, and self-pay routes before any forecast is locked.

    Three treatment routes compete for the same patient: prescription pharmacotherapy, bariatric and metabolic surgery, and obesity clinic programmes. Prescribing is distributed across endocrinologists, family physicians, internal medicine, bariatric surgeons, and obesity-clinic physicians. A physician survey that models only one route or one specialty misreads the market.

    Signals

    Regional notes for a GLP-1 physician survey in Saudi Arabia

    Riyadh

    Deepest concentration of endocrinology capability, bariatric centres, and premium obesity clinics, and the market where private weight-management pricing is set.

    Jeddah and the Western Region

    Strong bariatric surgery tradition and dense private clinic competition, with a large insured population and active self-pay weight-management demand.

    Eastern Province

    Dammam and Al Khobar combine employer-insured coverage and company-linked healthcare with corporate wellness programmes that surface undiagnosed metabolic risk. Saudi fieldwork is coordinated from the Al Khobar partner office for KSA.

    Secondary cities and interior regions

    Growing clinic presence with heavier reliance on family physicians and greater out-of-pocket sensitivity, where persistence on therapy is typically the binding constraint.

    Fieldwork

    Who we interview for Saudi GLP-1 physician surveys

    Endocrinologists and metabolic physicians

    Clinical leaders in weight management, interviewed on patient selection, dose escalation, monitoring, and long-term therapy expectations.

    Family physicians and internal medicine

    High-volume initiators interviewed on referral thresholds, confidence with anti-obesity medicines, and practical barriers to prescribing.

    Bariatric and metabolic surgeons

    Surgeons whose referral relationships and procedure volumes are affected by pharmacotherapy, interviewed on patient selection and combined pathways.

    Obesity-clinic physicians and pharmacists

    Private obesity-clinic physicians and pharmacists interviewed on package design, dispensing, supply interruptions, and cash-pay behaviour.

    Payers and insurance medical directors

    Medical directors under Council of Health Insurance (CHI) regulated plans, researched on weight-management coverage policy and prior authorisation.

    Patients and treatment considerers

    People currently treated or actively seeking weight management, researched on journey, expectations, cost tolerance, and reasons for discontinuation.

    Saudi fieldwork is coordinated from the Al Khobar partner office for KSA. The USA (Sheridan, Wyoming) is the Americas office and global HQ. The UK (London) is the Europe office. Cairo is the AMEA (APAC, Middle East, Africa) office. Dubai is a field office for UAE. Kuwait is a field office for Kuwait. São Paulo is a field office for LATAM.

    Physician survey

    GLP-1 physician survey methodology in Saudi Arabia

    BioNixus designs GLP-1 physician surveys in Saudi Arabia as commissioned primary research, scoped to the brand decision. A typical instrument covers the modules below.

    1. Screeners: specialty, sector (public or private), region (Riyadh, Jeddah and the Western Region, Eastern Province including Al Khobar and Dammam, secondary cities), and monthly obesity or metabolic caseload.
    2. KAP modules: guideline familiarity; comfort initiating anti-obesity medicines; perceived barriers such as training, supply, cost, and stigma.
    3. Prescribing behaviour: share of eligible patients offered an anti-obesity medicine; first-line choice among semaglutide, tirzepatide, and other agents; diabetes versus obesity indication mix.
    4. Access filters: prior authorisation experience; NUPCO and formulary constraints; self-pay share.
    5. Persistence signals: reasons patients discontinue; monitoring burden; referral to bariatric surgery.

    Modes: online quantitative with optional CATI; Arabic and English; depth interviews for KOLs and medical directors. Sample frames are stratified across endocrinology, family medicine, internal medicine, and bariatric surgery — the same specialty split highlighted in independent Saudi anti-obesity medicine research (PMC12366907). Deliverables include crosstabs, specialty segmentation, message implications, and forecast inputs. Scoped custom projects typically cost $10,000–$60,000.

    Method

    How we size and validate obesity market research in Saudi Arabia

    • →Physician survey sample frame stratified across endocrinology, family medicine, internal medicine, bariatric surgery, and obesity clinics, balanced by region and public or private sector.
    • →Depth interviews and quantitative validation on patient selection, initiation triggers, monitoring, switching, and the evidence that would change prescribing behaviour.
    • →Payer research with insurers and third-party administrators covering coverage policy, prior authorisation, and employer plan variation under Council of Health Insurance (CHI) rules.
    • →Patient journey research with screened treated and treatment-seeking respondents, focused on expectations, cost tolerance, and drivers of discontinuation.
    • →Bottom-up opportunity model reconciling eligible population, access route, initiation, and persistence, with pricing and access recommendations by sector and channel.

    Why BioNixus

    Why teams choose BioNixus for Saudi obesity market research

    BioNixus brings global reach with local rigour — operating across the Americas, EMEA, and APAC with the country-level depth that generic research cannot replicate. Founded in regulated healthcare, we apply the same methodological standards to life sciences (pharma, biotech, medtech) and to adjacent sectors including B2B, FMCG, and industrial markets. We translate KOL, payer, and hospital evidence — and where relevant, buyer, channel, and consumer insight — into launch, access, and growth strategies built for board-level scrutiny.

    • ✓Access is the core market-research question, because coverage inconsistency defines addressable volume for semaglutide and tirzepatide.
    • ✓Persistence and discontinuation research with patients, which is where obesity forecasts most often fail when much demand is self-pay.
    • ✓Coverage of pharmacotherapy, surgery, and clinic programmes, so a physician survey models route substitution instead of a single pathway.
    • ✓Prescriber segmentation across endocrinology, primary care, and bariatric surgery, reflecting how initiation volume is distributed in the Kingdom.
    • ✓Arabic and English fieldwork with clinicians and patients, coordinated from the Al Khobar partner office for KSA.
    • ✓Senior-led custom studies, typically $10,000–$60,000, with a costed proposal returned within one working day.

    Questions

    Frequently asked questions

    Can BioNixus run a GLP-1 physician survey in Saudi Arabia?

    Yes. BioNixus fields GLP-1 physician surveys and KAP studies in Saudi Arabia among endocrinology, family medicine, internal medicine, and bariatric surgery, in Arabic and English. Instruments cover initiation, switching between semaglutide and tirzepatide, access barriers, and persistence. Fieldwork is coordinated from the Al Khobar partner office for KSA. The physician network is 82,000+ physicians globally and about 3,200 physicians in the Middle East, with 127 studies year-to-date in 2026.

    Who does obesity market research in Saudi Arabia?

    BioNixus does obesity market research in Saudi Arabia. Saudi fieldwork runs from the Al Khobar partner office for KSA. Cairo is the AMEA (APAC, Middle East, Africa) office. The UK is the Europe office. The USA is the Americas office and global HQ in Sheridan, Wyoming. Dubai is a field office for UAE. Kuwait is a field office for Kuwait. The work covers GLP-1 physician surveys and KAP studies across endocrinology, family medicine, internal medicine, and bariatric surgery; patient-journey and discontinuation studies; and SFDA, NUPCO, and CHI access interviews, in Arabic and English. It is commissioned primary research, not a syndicated pack, typically $10,000–$60,000, with a costed proposal within one working day. The comparison of other providers is in Who does obesity market research in Saudi Arabia?.

    Is semaglutide for weight loss reimbursed in Saudi Arabia?

    Coverage is inconsistent: NUPCO public pathways, CHI private cover varies, and much is out of pocket. BioNixus checks the current route with payer and physician interviews rather than assuming one national rule.

    How do tirzepatide and semaglutide compete in the Saudi obesity market?

    Both molecules sit in the incretin and anti-obesity medicine set. Competitive share, diabetes versus obesity indication mix, supply, and self-pay economics differ by specialty and sector. BioNixus measures that with molecule-level physician surveys and pharmacy and clinic channel work, not with a single headline market number.

    How does BioNixus differ from IQVIA or a syndicated obesity report?

    IQVIA publishes syndicated prescription audits. Ken Research, IMARC, Euromonitor, Mordor, and Grand View publish market-size packs. Kantar runs brand tracking, and NielsenIQ covers retail. BioNixus runs commissioned primary research: named HCP quotas, Arabic fieldwork, and molecule-level semaglutide and tirzepatide modules, typically $10,000–$60,000. Use the syndicated source that fits the question, and brief BioNixus when the decision needs primary evidence.

    Where is BioNixus based?

    The USA (1309 Coffeen Ave Ste 1200, Sheridan, Wyoming 82801) is the Americas office and global HQ. The UK (128 City Road, London EC1V 2NX) is the Europe office. Cairo (22 Beverly Hills, Second Sheikh Zayed, Giza 3240232) is the AMEA (APAC, Middle East, Africa) office. Al Khobar is a partner office for KSA. Dubai (Thuraya Tower 1, 5th Floor, Al Sufouh 2) is a field office for UAE. Kuwait (Salmiya) is a field office for Kuwait. São Paulo is a field office for LATAM.

    What does obesity market research in Saudi Arabia cost?

    Custom obesity and GLP-1 studies typically cost $10,000–$60,000. BioNixus returns a costed proposal within one working day. The physician network is 82,000+ physicians globally and about 3,200 physicians in the Middle East, with 127 studies year-to-date in 2026.

    Get a scoped proposal in 48 hours

    Name the brand, the country, and the breakdown your syndicated feed cannot give you. We send a project- and country-priced proposal — typically within 48 hours.

    Email us

    US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323